Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Late-Stage Pipeline

67%

4 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 4
4(80.0%)
N/A
1(20.0%)
5Total
Phase 4(4)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT07213765Phase 4Recruiting

Short-term Antibiotic Therapy in Mycobacterium Avium Complex Pulmonary Disease

Role: lead

NCT07084402Phase 4Recruiting

Short-term Bactericidal Effect of Contezolid in MAC-PD

Role: lead

NCT07174076Phase 4Recruiting

Prevention of Recurrence With Cordyceps Sinensis in Mycobacterium Avium Complex Pulmonary Disease

Role: lead

NCT06756191Phase 4Not Yet Recruiting

Antifungal Drugs in Pulmonary Mucormycosis

Role: lead

NCT03594032Unknown

Prevalence and Characteristics of Patients With Bronchiectasis Comorbid Nontuberculous Mycobacteria

Role: lead

NCT03391076Not ApplicableUnknown

The Clinical Value of FA in AHLRI Patients

Role: lead

All 6 trials loaded